GlassScriptPhysician profile
Nicholas James Farber
NPI 1952716730
$13,666.74
in general payments reported to CMS, 2019-2025
44 companies · $2,151 in 2025
The $2,151 reported for 2025 was more than what 81% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,108 · 2020: $304 · 2021: $2,587 · 2022: $3,170 · 2023: $1,889 · 2024: $1,459 · 2025: $2,151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,148 · Honoraria: $350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,148.23 |
| Honoraria | $350.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $3,453.97 | 2019-2025 | Titan, Speedicath |
| Teleflex LLC | $1,894.47 | 2021-2025 | Urolift, Barrigel |
| Endo Pharmaceuticals INC. | $1,893.34 | 2020-2024 | Xiaflex, Aveed |
| Boston Scientific Corporation | $1,510.96 | 2019-2020 | |
| Medtronic, INC. | $888.41 | 2021-2025 | Interstim |
| Endo USA, INC. | $488.95 | 2024-2025 | Xiaflex, Aveed |
| Astellas Pharma US INC | $393.57 | 2020-2025 | Xtandi, Myrbetriq |
| Sumitomo Pharma America, INC. | $352.27 | 2023-2025 | Gemtesa, Orgovyx |
| Dendreon Pharmaceuticals LLC | $307.40 | 2021-2025 | Provenge |
| Antares Pharma, INC. | $276.95 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Urovant Sciences INC | $179.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $167.23 | 2021-2025 | |
| Myovant Sciences INC. | $156.83 | 2021-2022 | |
| Abbvie INC. | $152.49 | 2022-2025 | |
| Baxter Healthcare | $148.24 | 2021-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tolmar, INC. | $144.04 | 2023-2024 | |
| Blue Earth Diagnostics | $134.32 | 2021-2022 | |
| Pfizer INC. | $132.27 | 2021-2024 | |
| Neotract INC. | $94.80 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $68.77 | 2023-2024 | Lynparza |
| Rigicon,INC. | $64.75 | 2023 | Rigi10 Malleable Penile Prosthesis |
| Convatec INC. | $59.87 | 2022-2023 | |
| Axonics, INC. | $56.22 | 2024 | Axonics, Bulkamid |
| Laborie Medical Technologies Corp. | $54.55 | 2023-2025 | Optilume Bph Drug Coated Balloon Catheter |
| Merck Sharp & Dohme LLC | $48.05 | 2022-2023 | Lynparza, Welireg, Keytruda |
| Kowa Pharmaceuticals America, INC. | $47.85 | 2022-2023 | Seglentis |
| Myriad Genetic Laboratories, INC. | $47.22 | 2021-2023 | Prolaris |
| Allergan, INC. | $43.97 | 2020-2022 | |
| Olympus America INC. | $42.93 | 2021-2025 | Itind System |
| Halozyme INC | $38.71 | 2023 | |
| Ferring Pharmaceuticals INC. | $36.39 | 2024-2025 | Adstiladrin |
| Acerus Pharmaceuticals Corporation | $30.24 | 2021 | |
| Janssen Biotech, INC. | $29.76 | 2025 | Erleada |
| Vertex Pharmaceuticals Incorporated | $29.40 | 2025 | |
| Ambu INC. | $28.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $26.08 | 2025 | |
| Verity Pharmaceuticals INC. | $25.83 | 2025 | Tlando |
| Tolmar Pharmaceuticals, INC. | $24.33 | 2022 | |
| Davol INC. | $20.65 | 2021 | |
| Mission Pharmacal Company | $19.19 | 2022 | |
| Rochester Medical Corporation | $19.13 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $16.14 | 2024 | Eylea Hd |
| Allegis Pharmaceuticals, LLC | $13.48 | 2023 | Urimar-T Caps |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Farber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.